Semaglutide

Long-Acting GLP-1 Analog for Metabolic Pharmacology Research

Semaglutide is a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) engineered with three key modifications: an aminoisobutyric acid (Aib) substitution at position 8 to resist DPP-4 degradation, a C-18 fatty diacid side chain attached via a γGlu-2xOEG linker at Lys²⁶ for albumin binding and prolonged half-life, and an arginine-to-lysine substitution at position 34 (sequence: HXEGTFTSDVSSYLEGQAAKEFIAWLVKGRG; where X=Aib). These modifications create a research tool with significantly extended in-vivo activity compared to native GLP-1, allowing scientists to study the effects of sustained GLP-1 receptor activation on glucose-dependent insulin secretion, glucagon suppression, gastric emptying, satiety signaling, and potential neuroprotective/cardioprotective pathways. Supplied as the research-grade base peptide (not a specific salt form), this lyophilized compound is intended strictly for controlled, non-human laboratory investigation into the mechanisms of next-generation incretin therapies.

Complete Research Kit Contents & Verification

Each research order provides a complete experimental package designed for sophisticated pharmacological research:

• Primary Research Compound: 10 sterile glass vials containing 5mg of lyophilized Semaglutide base peptide powder per vial.

• Reconstitution Solution: 30ml vial of sterile Bacteriostatic Water (0.9% Benzyl Alcohol). Note: For certain in-vitro assays, researchers may prefer specific buffers to maintain albumin-free conditions for binding studies.

• Laboratory Administration Tools: Pack of sterile syringes (1ml insulin syringes for precision, 3ml for reconstitution) with various gauges and alcohol swabs.

• Research Protocol Documentation:

  • Dosing Schedule: Administration protocol for research models, accounting for the peptide’s extended half-life (suitable for intermittent dosing in chronic studies).

  • Usage Instructions: Critical guide covering the specific handling of this acylated peptide: gentle reconstitution to avoid foaming/aggregation, stability considerations (albumin binding in biological matrices), storage at -20°C to -80°C, and avoidance of adsorption to surfaces.

• Quality Verification: Certificate of Analysis (CoA) provided with each batch, detailing:

  • Purity Analysis (>97% by HPLC/UPLC – critical due to complexity)

  • Structural Verification (Mass Spectrometry):

    • Confirmation of Aib at position 8

    • Confirmation of C-18 fatty diacid acylation at Lys²⁶ via linker

    • Full sequence confirmation

  • Molecular Weight Confirmation (~4114 Da)

  • Related Substances & Degradation Products (e.g., deamidation, dimerization)

  • Sterility Testing Results

  • Endotoxin Levels (<10 EU/mg)

  • Residual Solvents (from synthesis & acylation)

  • Free Fatty Acid Content & Acylation Efficiency

Research Applications & Scientific Utility

In a laboratory setting, research-grade Semaglutide enables high-level investigation into sustained GLP-1 pharmacology. Primary research applications include:

• Chronic Disease Models: Studying long-term metabolic effects in diet-induced obesity, type 2 diabetes, and NAFLD/NASH models with weekly or less frequent dosing schedules.

• Mechanism of Prolonged Action: Investigating the kinetics of albumin binding, tissue distribution, and receptor activation over extended periods.

• Comparative Pharmacology: Serving as a gold-standard comparator for evaluating novel GLP-1 analogs, dual/triple agonists, or other long-acting formulations in development.

• Non-Metabolic Effects: Researching potential benefits in neurodegenerative (Alzheimer’s, Parkinson’s) or cardiovascular disease models, independent of weight loss.

• Combination Therapy Research: Exploring synergistic effects with other hormone analogs (e.g., amylin, GIP agonists) in metabolic studies.

Laboratory Handling & Safety Protocol – SPECIAL CONSIDERATIONS

• Storage: Store unopened vials at -20°C or preferably -80°C. The fatty acid chain can oxidize. Aliquot reconstituted solution immediately and store at -80°C. Avoid repeated freeze-thaw cycles.

• Reconstitution: Crucial Step. Use the provided bacteriostatic water. Add slowly down the vial wall. Let sit for 30-60 minutes at 4°C, then swirl very gently. Do NOT shake or vortex. The solution may appear slightly opalescent due to the fatty acid chain; this is normal if mild.

• Binding & Adsorption: This peptide readily binds to albumin and may adsorb to plastic. Use low-binding tubes and account for this in dose calculations for in-vivo work. For cell studies, pre-incubate with media containing serum.

• Laboratory Safety: Standard PPE required. Handle as a potent, long-acting biological research compound.

⚠️ Critical Compliance & Intended Use Disclaimer:

THIS PRODUCT IS SOLD FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

1. Intended Use: Semaglutide is supplied as a biochemical reagent for laboratory research purposes only. It is intended for use by qualified researchers in controlled non-human settings. The “dosing schedule” is for research models only.

2. Not for Human Consumption: This product is NOT Ozempic®, Wegovy®, or Rybelsus®. It is not a drug, weight loss treatment, or diabetes medication. It is a raw peptide for research. The provided supplies are for laboratory use.

3. Regulatory Status: This product has not been manufactured in an FDA-approved facility, nor has it been evaluated or approved for any use by the FDA or any global health authority.

4. Intellectual Property Notice: Semaglutide is a patented compound of Novo Nordisk A/S. This supply is for non-commercial research use only under applicable exemptions.

5. Researcher Responsibility: The purchaser assumes full responsibility for compliance with all laws and for ensuring this compound is used exclusively for legitimate, non-human research.